摘要
目的:探讨曲美他嗪对缺血性心肌病患者心率变异性的影响.方法:选择60例缺血性心肌病患者,随机分为常规治疗组及曲美他嗪治疗组各30例,后者在常规治疗基础上加用曲美他嗪(20 mg,3次/d),疗程24周.治疗前后通过动态心电图测定心率变异性(HRV)指标(SDNN、SDANN、rMSSD、PNN50、HF、LF、LF/HF).结果:曲美他嗪组和常规治疗组治疗后SDNN、SDANN、rMSSD、PNN50、HF均高于治疗前(P<0.01或P<0.05),LF、LF/HF低于治疗前(P<0.01或P<0.05);曲美他嗪组治疗前后SDNN、SDANN、rMSSD和PNN50变化值均高于常规治疗组(P<0.01或P<0.05),而LF和LF/HF均低于常规治疗组(P<0.05).提示两组治疗前后心率变异性各指标均有改善,曲美他嗪组改善更为显著.结论:曲美他嗪能在常规治疗的基础上进一步提高缺血性心肌病患者的心率变异性.
Objective： To discuss the effect of trimetazidine on heart rate variability in patients with ischemic cardiomyopathy.Methods：60 patients with ischemic cardiomyopathy were randomly divided into standard therapy group and trimetazidine group.The patients in latter group were added trimetazidine（20 mg tid for 24 weeks） in addition to standard therapy.While heart rate variability（SDNN,SDANN,rMSSD,PNN50,HF,LF,LF/HF）were determined by Holter.Results：In both trimetazidine and standard therapy groups,SDNN,SDANN,rMSSD,PNN50,HF were higher after treatment（P 0.01 or P 0.05）;LF,LF/HF were lower after treatment（P 0.01 or P 0.05）.In the trimetazidine group,the changing value of SDNN,SDANN,rMSSD,PNN50 before and after treatment were higher than the indexes in standard therapy group（P 0.01 or P 0.05）,and LF,LF/HF are lower（P 0.05）.Suggested that the heart rate variability parameters improved in both groups after treatment.The more significant improvement was observed in trimetazidine group.Conclusion：On the basis of standard therapy,trimetazidine can further improve heart rate variability in patients with ischemic cardiomyopathy.
出处
《江汉大学学报（自然科学版）》
2011年第1期75-77,共3页
Journal of Jianghan University：Natural Science Edition
关键词
缺血性心肌病
曲美他嗪
心率变异性
ischemic cardiomyopathy
trimetazidine
heart rate variability（HRV）
